07:46 AM EDT, 03/18/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.

The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.

Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.

Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.